RHEUMATOLOGY / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Antinuclear antibodies (ANA) are frequently positive in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM). This study aimed to investigate the association between ANA and clinical characteristics as well as prognosis in a cohort of patients with anti-MDA5+ DM.

Material and methods:
We conducted a systematic retrospective study of medical records from a Nanjing Medical University cohort of patients with myositis-associated interstitial lung disease (ILD). Various parameters were compared and analyzed between the ANA-positive group and the ANA-negative group.

Results:
A total of 246 patients with anti-MDA5+ DM were enrolled in this study, with 28.5% males and 71.5% females. The median age was 53.0 years, the median disease duration was 2 months, and the median follow-up period was 12.0 months. The ANA positivity rate at baseline was 52.4% in anti-MDA5+ DM patients. The ANA-positive group showed significantly higher positivity rates of anti-Ro52 antibodies (72.9% vs. 54.7%, p = 0.003) and anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies (9.3% vs. 2.6%, p = 0.033) compared to the ANA-negative group, but lower ALT levels: 39.0 (21.5, 79.3) vs. 51.3 (36.5, 95.8), p = 0.006. No significant differences were observed between the two groups in terms of overall survival, rapidly progressive interstitial lung disease (RPILD) incidence, age, disease duration, and clinical characteristics. In a subgroup analysis of the ANA-positive group, MDA5+++ patients had a higher incidence of RPILD compared to the MDA5+ group (p = 0.028). In the ANA-negative subgroup analysis, MDA5+++ patients had a higher mortality rate and worse prognosis compared to the MDA5+ group (p = 0.026). Multivariate Cox regression analysis showed that elevated lactate dehydrogenase (LDH) levels and the presence of rapidly progressive interstitial lung disease (RPILD) were associated with poor prognosis in ANA-negative anti-MDA5+ DM patients, with hazard ratios of 1.002 (95% CI: 1.001, 1.003, p = 0.020) and 13.694 (95% CI: 15.032, 37.267, p < 0.001), respectively.

Conclusions:
ANA is frequently found in patients with anti-MDA5+ DM. High titers of anti-MDA5 antibodies are associated with mortality and RPILD.
REFERENCES (21)
1.
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 2020; 82: 267-81.
 
2.
Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nature reviews. Rheumatology 2024; 20: 48-62.
 
3.
Ling M, Murali M. Antinuclear antibody tests. Clin Labor Med 2019; 39: 513-24.
 
4.
Satoh M, Vázquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Modern Rheumatol 2009; 19: 219-28.
 
5.
Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology 2020; 95: e70-8.
 
6.
Jin Q, Fu L, Yang H, et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Inter Med 2023; 293: 494-507.
 
7.
Ceribelli A, Isailovic N, De Santis M, et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 2017; 36: 469-75.
 
8.
Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27: 1050-6.
 
9.
Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, et al. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. J Am Acad Dermatol 2019; 80: 1364-70.
 
10.
Cheng L, Xu L, Xu Y, et al. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases. Clin Rheumatol 2024; 43: 339-47.
 
11.
Xu L, You H, Wang L, et al. Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease. Arthritis Rheumatol 2023; 75: 609-19.
 
12.
Lv C, You H, Xu L, et al. Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J Rheumatol 2023; 50: 219-26.
 
13.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
 
14.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
 
15.
Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 1996; 34: 824-9.
 
16.
Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6.
 
17.
Abe Y, Kusaoi M, Tada K, et al. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology 2020; 59: 767-71.
 
18.
Liu H, Wang Y, Wang P, et al. Clinical significance of serum antinuclear antibodies in patients with autoimmune hepatitis and comorbidity. Clin Exp Med 2023; 23: 3453-63.
 
19.
Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol 2016; 174: 158-64.
 
20.
Nishikai M, Sato A. Low incidence of antinuclear antibodies in dermatomyositis with malignancy. Ann Rheum Dis 1990; 49: 422.
 
21.
Li YH, Yao HH, Zhang XW, et al. Analysis for the organ involvement and immnunological markers of the patients with dermatomyositis. Beijing Da Xue Xue Bao Yi Xue Ban 2010; 42: 140-2.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top